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ABSTRACT. 
 
Oligonucleotides containing 6-N-([13C]methyl)adenine and 2-N-
([13C]methyl)guanine have been prepared for NMR studies using the 
deprotection step to introduce the [13C]methylamine group. For this 
purpose, the use of 2’-deoxy-6-O-(pentafluorophenyl)inosine 1 and 2’-
deoxy-2-fluoro-6-O-[2-(4-nitrophenyl)- ethyl]inosine 2 as precursors of the 
N-methylated nucleosides is described. Preliminary NMR characterization of 
the 13C-labelled oligonucleotides shows that the 13C chemical shift of the 
methyl group in N-methylguanine is sensitive to duplex formation, making it 
a useful local probe. 
 
Introduction 
 
One of the problems found during the structural elucidation of DNA–
protein interactions is the complexity of the spectra. The introduction of 15N 
and 13C in combination with special pulse sequences allows the selective 
observation of specific base pairs.[1] Although a large effort has been 
devoted to the preparation of oligodeoxynucleotides having 15N labels,[1] 
there are few examples of 13C-labelled oligodeoxynucleotides at specific 
sites. A thymidine phosphoramidite labelled at C-6 with 13C has been 
prepared and incorporated into a synthetic hairpin oligonucleotide. [2] NMR 
relaxation measurements showed a higher internal motion in the loop 
region than in the duplex.[2,3] Also, oligonucleotides labelled with 13C at 
the thymine methyl groups have been prepared to study hydrophobic 
contacts between DNA and the DNA-binding domain of the rat glucocorticoid 
receptor.[4] The analysis revealed a hydrophobic contact between a labelled 
thymine group and the methyl groups of a valine residue. Base-pairing 
properties of 2-deoxy-5-(methoxymethyl)-uridine have also been studied by 
NMR spectroscopy using a heptanucleotide containing a 13C label at the 
exocyclic position of this analogue.[5] 
Recently, the development of nucleoside derivatives that can be 
transformed into different nucleoside analogues during deprotection has 
been described.[6–10] This method, named ‘the convertible nucleoside 
approach,’ has been used to prepare oligodeoxynucleotides containing 15N 
labels at exocyclic positions.[10–12] In the present communication we 
describe the preparation of oligodeoxynucleotides containing N-
methyladenine and N-methylguanine residues with a 13C label at the 
methylamino exocyclic position. The methodology described here uses a 
modified deprotection protocol to incorporate the 13C label and to our 
knowledge is the first time that 13C labels have been incorporated in the 
amino groups involved in base-pairing. 
 
Results and discussion 
 
Preparation of oligonucleotides containing N6-([13C]methyl)adenine 
 
Previous reports have shown that 6-chloropurine and 6-fluoropurine 
2’-deoxyriboside react with amines to produce adenine adducts at 
nucleoside [13–17] and oligonucleotide [18,19] levels. On the other hand, 
6-O-aryl-dI derivatives [8,9,12] have been described for the preparation of 
oligonucleotides containing modified adenines. Recently, use of 6-
(methylthio)purine has been described for the preparation of 6-substituted 
purines including 6-N-methyladenine.[20] We have selected 2’-deoxy-6-O- 
(pentafluorophenyl)inosine 1 (Scheme 1) as precursor of the N 
methyladenine residue because previous studies have shown that this 
derivative is stable to oligonucleotide synthesis conditions and reacts readily 
with amines even in the presence of water without detectable 
hydrolysis.[12] 
 
 
 
Scheme 1 Nucleoside derivatives used in this work for the preparation of 
oligonucleotides containing 6-N-([13C]methyl)adenine and 2-N- 
([13C]methyl)guanine 
 
 
 
2’-Deoxy-6-O-(pentafluorophenyl)inosine [12] 1 was prepared 
following previously described protocols. Overnight treatment of 2’-deoxy-6-
O-(pentafluorophenyl)inosine with aq. Methylamine (prepared by addition of 
triethylamine to aq. CH3NH2 ● HCl) at 60 ºC yielded the desired 29-deoxy-
N-methyladenosine as the only nucleoside product that was isolated and 
characterized.  
When amines are used for the deprotection of synthetic 
oligonucleotides, approximately 10–20% of the N-benzoylcytidine residues 
react with the amine, yielding the corresponding 4-N-alkylcytidine [6] 
derivatives. This side reaction can be minimized by use of other protected 
derivatives of cytidine.[21,22] Among them, tert-butylphenoxyacetyl [23] 
(ExpediteTM) protective groups were selected. A short oligonucleotide 
containing 3 cytosines (5’-CCCAT-3’) was prepared using tert-
butylphenoxyacetyl phosphoramidites. At the end of the synthesis, the 
support was treated overnight at 60 8C with aq. methylamine (prepared by 
addition of triethylamine to an aq. CH3NH2 ● HCl). The resulting 
oligonucleotide was purified by HPLC and analysed by enzyme digestion. 
Only dC, dA and T were found. The product resulting from the attack of 
methylamine on protected cytidine, 4-N-methyl-dC, was not detected. An 
authentic sample of 4-Nmethyl- dC was prepared from 4-O-ethyl-dU to 
determine the position at which 4-N-methyl-dC elutes.  
The dodecamer having the recognition sequence of E. coli methylase 
(5’-GCGAIpfTTCGCGC-3’ with Ipf being 6-O-pentafluorophenyl- dI) was 
prepared using tert-butylphenoxyacetyl and 6-O-pentafluorophenyl-dI [12] 
phosphoramidites. Treatment of the support with aq. [13C]methylamine 
overnight at 60 ºC yielded a main product that was purified by HPLC using 
standard protocols. We used 250 mg of [13C]methylamine hydrochloride per 
2 µmols of oligonucleotide, which is approximately 90 times the amount 
needed to remove the protecting groups and perform the substitution. 
Enzyme digestion showed the presence of the four natural nucleosides 
together with 6-N-methyl- dA in the expected proportions (see Fig. 1). 
 
Fig. 1 Enzymic digestion of purified 6-N-([13C]methyl)adenine dodecamer {5’-
GCGAA*TTCGCGC-3’ where A* is 6-N-([13C]- methyl)adenine} 
  
Fig. 2 Enzymic digestion of purified 2-N-([13C]methyl)guanine dodecamer {5’-
CACCG*ACGGCGC-3’ where G* is 2-N-([13C]- methyl)guanine} 
 
Preparation of oligonucleotides containing 2-N-
([13C]methyl)guanine 
 
For the introduction of 13C label at position 2 of guanine, 2’- deoxy-2-
fluoroinosine was selected. This nucleoside and its protected derivatives 
have been used as precursors of 2-amino substituted guanine derivatives at 
the nucleoside and oligonucleotide level.[13,14,19,24–27] 2’-Deoxy-2-
fluoro-6-O-[2-(4-nitrophenyl) ethyl (NPE)]inosine [12] 2 (Scheme 1) was 
prepared as previously described. Treatment of compound 2 with aq. 
methylamine at 60 ºC gave the desired 2-N-methyl-dG as the major 
product. Small amounts (less than 10%) of NPE-protected 2-N-methyl-dG 
were also observed, but the hydrolysis product (dG) was not detected. 
When treatment with methylamine was performed at room temperature for 
16 h, two products were obtained: NPE-protected 2-N-methyl-dG and 2-N-
methyl-dG, together with small amounts of starting material (data not 
shown). This indicates that the displacement of fluoride by methylamine is 
easier than the removal of the NPE group. 
The dodecamer 5’-CACCIfACGGCGC-3’ (R5) [28] with If = 2- fluoro-6-
O-NPE-dI, was prepared using tert-butylphenoxyacetyl and 2-fluoro-6-O-
NPE-dI [12] phosphoramidites. After the assembly of the sequence, the 
support was treated with a 0.5 M solution of 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) solution in acetonitrile at room temperature for 15 min to 
remove the NPE group. Under these conditions loss of oligonucleotide by 
cleavage of the succinyl bond is negligible [12,29] and the majority of the 
NPE groups at position 6 in the guanine are removed. Treatment of the 
support with aq. [13C]methylamine overnight at 60 ºC yielded a main 
product that was purified by HPLC using standard protocols. Enzyme 
digestion showed the presence of dC, dG and dA together with 2-N-methyl-
dG in the expected proportions (Fig. 2). Moreover, mass spectral analysis of 
the purified product by matrix-isolated laser-desorption time-of-flight mass 
spectrometry (MALDI-TOF) gave the expected molecular mass (Found: M1, 
3631.2, expected M, 3631). In this oligonucleotide we used 63 mg of 
[13C]methylamine hydrochloride per 4 µmols of oligonucleotide, which is 10 
times the amount needed for removal of the protecting groups. The cost of 
the 13C label in this preparation is lower than the cost of the chemicals 
needed to produce the oligonucleotide. The 1D proton spectrum at 600 MHz 
of the dodecamer revealed a homogeneous product with sharp signals. To 
confirm the labelled methyl group was on the guanine moiety a 2D 
heteronuclear multiple quantum filtered coherence (HMQC) [30] spectrum 
was recorded in which the carbon signals are indirectly detected via the 
proton resonances of the coupled spins. This inverse spectrum of the 
oligonucleotide showed very clearly two antiphase satellites only at a 
centred resonance frequency of δ[1H] 2.58 split by a coupling constant of 
137 Hz for the C-H coupling (data not shown). 
A proton-decoupled carbon spectrum of R5 showed a carbon signal at 
δ[13C] 34.37, which was assigned to the 13CH3 group of 2-N-methyl-G (see 
Fig. 3), also confirmed by a gated decoupled spectrum (quadruplet at the 
same frequency). The change of the chemical shift of the 13CH3 group of 2-
N-methyl- G on comparing the spectrum of R5 dodecamer with the 
spectrum of the two annealed complementary oligonucleotides (δ[13CH3] = 
32.84, ∆δ 1.53 ppm) reveals a hybridization of the two strands.  
 
In summary, we have shown that oligonucleotides carrying 6-N-
([13C]methyl)adenine and 2-N-([13C]methyl)guanine bases can be easily 
prepared using the phosphoramidites of 6-O-pentafluorophenyl- dI and 2-
fluoro-6-O-NPE-dI together with a special deprotection protocol using 
[13C]methylamine. Under these conditions, oligonucleotides are deprotected 
and released from the solid support and the modified nucleoside is 
converted into the desired 6-N-([13C]methyl)adenine and 2-N-
([13C]methyl)- guanine residues. Modification of C residues described [6] for 
4-N-benzoyl dC is avoided by using tert-butylphenoxyacetylprotected 
phosphoramidites. [23] The method is simple and efficient and the 
introduction of the label is at the end of the synthetic process. The 
introduction of the methyl group does not disturb the formation of the 
duplex as shown in previous reports.[31,32] Preliminary NMR 
characterization showed that the 13CH3 group in 2-N-([
13C]methyl)guanine 
moved upfield upon duplex formation indicating that this type of labelling 
could be used to monitor duplex formation as well as protein–DNA 
interactions. 
 
 Fig. 3 13C NMR spectra of (a) dodecamer 5’-CACCG*ACGGCGC-3’ where G* 
is 2-N-([13C]methyl)guanine and (b) duplex formed by 5’- 
CACCG*ACGGCGC-3’ and 3’-GTGGCTGCCGCG-5’. The peak at δC 29.5 is the 
methyl carbon of acetate used as a reference. 
 
Experimental 
Abbreviations: ACN: acetonitrile, DCM: dichloromethane, DMT: 4,4’-
dimethoxytrityl, dIf: 2’-deoxy-2-fluoroinosine, dIpf: 2’-deoxy-6-O 
(pentafluorophenyl)inosine, pyr: pyridine. 2’- Deoxy-5’-O-(4,4’-
dimethoxytrityl)-6-O-(pentafluorophenyl)- inosine 3’-O-(2-cyanoethyl)-N,N-
diisopropylphosphoramidite, [12] 2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-2-
fluoro-6-O-[2-(4-nitrophenyl)ethoxycarbonyl]inosine 3’-O-(2-cyanoethyl)-
N,N-diisopropylphosphoramidite [12] and 5’-O-(4,4-dimethoxytrityl)- 4-O-
ethylthymidine [33] were prepared as described. ExpediteTM (tert-
butylphenoxyacetyl) phosphoramidites were from PerSeptive Biosystems. 
99% [13C]Methylamine hydrochloride was purchased from Cambridge 
Isotope Laboratories, Inc. 
 
HPLC conditions 
In all cases solvent A was 20 mM triethylammonium acetate (pH 7.8) 
and solvent B was a 1 : 1 mixture of water and acetonitrile. For analytical 
runs the following conditions were used. Columns: Nucleosil 120C18, 250 × 
4 mm, flow rate: 1 ml min-1 and Radial Pak C18, flow rate 2 ml min
-1. (A) 5–
95% B linear gradient in 40 min. (B) 5–50% B linear gradient in 20 min. For 
semipreparative runs the following conditions were used. Columns: 
Nucleosil 120C18, 250 × 10 mm and C4-Vydac, 250 × 10 mm. Flow rate: 3 
ml min-1. A 20–80% B linear gradient in 30 min for oligonucleotides 
containing the DMT group and a 5–50% B linear gradient in 30 min for 
oligonucleotides without the DMT group. 
 
NMR measurements 
The R5 sample contained 4.6 mM (60 O.D. units at 260 nm) of the 
purifed product in 0.6 ml of D2O at pH 6.8. The duplex sample consisted of 
1.2 mM (16 O.D. units) of each dodecamer (R5 and its complementary) in 
0.6 ml of D2O at pH 6.8. The 1D-proton and the HMQC spectra were 
recorded on a Bruker 600 MHz spectrometer, the chemical shifts were 
referenced to D2O at δ 4.75. Carbon spectra were recorded on a Bruker AM 
250 MHz spectrometer with proton decoupling. The spectra were recorded 
at 298 K, TD = 16K, with a spectral width of 14 000 Hz corresponding to 
220 ppm and an acquisition time of 0.59 sec, zero filling to 64K points after 
Gaussian multiplication. The methyl carbon of the acetate at δC 29.5 ppm 
was used as internal reference in both samples. 
 
Conversion of 2’-deoxy-6-O-(pentafluorophenyl)inosine into 2’-
deoxy-6-N-methyladenosine 
2’-Deoxy-6-O-(pentafluorophenyl)inosine 12 (0.37 mmol) was 
dissolved in 2 ml of water and methylamine hydrochloride (7.4 mmol) and 
triethylamine (7.4 mmol) were added. The solution was heated at 60 ºC 
overnight. The resulting solution was concentrated to dryness and the 
residue was purified on silica gel column chromatography with a 5–10% 
MeOH gradient in DCM. Yield of product 0.2 g (52%). UV spectrum as 
previously described. [34] TLC (10% MeOH–DCM) Rf 0.26; HPLC (conditions 
A): one peak at tR 16.2 min. The product migrated together with 
commercially available 2’-deoxy-6-N-methyladenosine (Sigma); δH(CDCl3; 
200 MHz) 8.3 (1 H, s, H-2), 7.9 (1 H, s, H-8), 6.4 (1 H, m, H-1’), 6.3 (1 H, 
m, OH-3’), 5.1 (1 H, m, OH-5’), 4.4 (1 H, m, H-3’), 4.3 (1 H, m, H-4’), 3.9 
(2 H, m, H2-5’), 3.1 (3 H, s, NCH3), 2.9 (1 H, m, H-2’) and 2.5 (1 H, m, H-
2’); δC(CDCl3; 75 MHz) 155.3, 152.0, 146.0, 139.2, 122.1, 121.7, 89.3, 
87.2, 72.1, 63.0, 40.4 and 13.3 (N CH3). 
 
Preparation of 2’-deoxy-4-N-methylcytidine 
2’-Deoxy-5’-DMT-4-O-ethyluridine [33] (40 mg, 0.07 mmol) was 
treated with a solution of methylamine hydrochloride (3.6 mmol) and 
triethylamine (3.6 mmol) in water (2 ml). ACN was added until a clear 
solution was obtained. The solution was heated at 55 ºC overnight and 
concentrated to dryness. The residue was treated with aq. 80% acetic acid 
for 15 min at room temperature. The solution was concentrated to dryness 
and the residue was purified on silica gel and eluted with a 10–30% MeOH 
gradient in DCM. Yield of product 17 mg (90%). Physical data and UV 
spectra as previously described. [31,35] TLC (20% MeOH–DCM) Rf 0.13; 
HPLC (conditions A): one peak at tR 9.7 min; δH(CD3OD; 200 MHz) 7.8 (1 H, 
d, J 6.3, H-6), 6.3 (1 H, t, J 6.4, H-1’), 6.0 (1 H, d, J 6.3, H-5), 4.4 (1 H, m, 
H-3’), 4.0 (1 H, m, H-4’), 3.8 (2 H, m, H2-5’), 2.3 (2 H, m, H2-2’) and 2.9 (3 
H, s, NCH3). 
 
Conversion of 2’-deoxy-2-fluoro-6-O-[2-(4-nitrophenyl)ethyl]-
inosine into 2’-deoxy-2-N-methylguanosine 
2’-Deoxy-2-fluoro-6-O-[2-(4-nitrophenyl)ethyl]inosine [12] (150 mg, 
0.35 mmol) was dissolved in 1 ml of 20% methylamine (5 mmol) in water. 
The solution was incubated at 60 ºC overnight. The resulting solution was 
evaporated to dryness. The residue was dissolved in 5% MeOH in DCM 
containing 1% triethylamine and was purified on a silica gel column eluted 
with a 10– 60% MeOH gradient in DCM containing 1% triethylamine. 
Fractions containing 2’-deoxy-2-N-methylguanosine (eluted between 40 and 
60% MeOH) were pooled and evaporated to dryness to yield the title 
compound (40 mg, 40%). Physical and chromatographic data as described 
previously. [36] TLC (30% MeOH in DCM) Rf 0.41; HPLC (conditions A): one 
peak at tR 13.6 min; δC[(CD3)2SO; 250 MHz] 156.9 (C-6), 153.2 (C-2), 
150.5 (C-4), 135.7 (C-8), 116.6 (C-5), 87.5 (C-49), 82.6 (C-19), 70.6 (C-
39), 61.8 (C-59), 39.5 (C-29) and 27.4 (CH3). 
 
Oligonucleotide syntheses 
The sequences A: 5’-CCCAT-3’, B: 5’-GCGAIpfTTCGCGC-3’ and C: 5’-
CACCIfACGGCGC-3’ were prepared on an Applied Biosystems automatic 
DNA synthesizer using tert-butylphenoxyacetyl 2-cyanoethyl 
phosphoramidites and the modified phosphoramidite of 2’-deoxy-5’-O-DMT-
6-O-(pentafluorophenyl) inosine. Sequence A was prepared on a 1 µmol 
scale without the DMT at the end, sequence B on a 2 µmol scale without 
DMT, and sequence C on a 4 µmol scale with the last DMT group. 
Oligonucleotide supports were deprotected with aq. Methylamine 
overnight at 60 ºC. Cold methylamine hydrochloride was used for sequence 
A and [13C]methylamine hydrochloride was used for sequences B and C.  
For sequences A and B the following protocol was used: Approx. 50–
100 mol equiv. of methylamine hydrochloride were dissolved in water (50 
mg of CH3NH2 ● HCl in 0.5 ml for sequence A and 250 mg of [
13C] CH3NH2 ● 
HCl in 1 ml for sequence B) and the solution was added to the support 
followed by an equimolar amount of triethylamine with respect the amount 
of CH3NH2 ● HCl (75 mg for sequence A and 374 mg for sequence B). The 
reaction mixtures were kept overnight in a screw-cap vial tightly closed 
inside the oven at 60 ºC.  
For sequence C the following protocol was used: The 
DMToligonucleotide support was treated with 0.5 M DBU in ACN at room 
temperature for 15 min. Afterwards, the support was washed successively 
with ACN, 1% Et3N solution in ACN (to remove DBU salts) and again with 
acetonitrile and was dried under vacuum. 10 Mol equiv. of [13C] CH3NH2 ● 
HCl (0.92 mmol, 63 mg) were dissolved in 0.5 ml of water, and 0.13 ml of 
Et3N (0.92 mmol) were added. This solution was added to the 
oligonucleotide support and the mixture was treated at 60 ºC for 16 h. After 
the treatment, the solutions were concentrated to dryness and the products 
were purified by reversed-phase HPLC (see conditions above). All syntheses 
presented a major peak that was collected and analysed by snake venom 
phosphodiesterase and alkaline phosphatase digestion followed by HPLC 
analysis of the nucleosides (conditions B, see above; and Figs. 1 and 2). 
Yield (O.D. units at 260 nm) : Pentamer A (1 µmol synthesis): 35 O.D.; 
dodecamer B (2 µmol): 60 O.D.; dodecamer C (4 µmol) : 170 O.D. Mass 
determination of the HPLC-purified product using MALDI showed a 
molecular peak at M1, 3631.18 as expected for the labelled oligonucleotide 
(expected mass 3631 amu).  
The complementary strand of R5 (5’-GCGCCGTCGGTG- 3’) was 
synthesized on a 1 µmol scale using standard protocols and the last DMT 
group was left on during deprotection with ammonia. This oligonucleotide 
group was purified from truncated sequences using COPTM (Cruachem Ltd., 
Scotland) cartridges.  
In order to avoid the triethylammonium signals in the NMR spectrum 
purified oligonucleotides were passed through a Dowex 50W (Na+-form) 
column. Remaining acetate ions were used as NMR reference. An amount of 
16 O.D. units of each strand were annealed at 65 ºC and cooled slowly to 
form the duplex before the carbon spectrum was recorded. 
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